Back to School on Biosimilars

Today the FDA announced a new education and awareness campaign that will help physicians better understand the world of biosimilars. First, what is a biosimilar?

The Challenges of Regulatory Review

The Trump Administration has said it is moving forward to slow down the pace of federal regulations and reduce regulatory costs. Recently, the Office of

C.H.I.P.

It’s August, which means officially Washington is in recess.  But it won’t be long before Congress returns in September and will need to act swiftly